Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group

被引:9
|
作者
Le Goff, Caroline [1 ]
Kaux, Jean-Francois [2 ]
Segura, Jordi Farre [3 ]
Stojkovic, Violeta [3 ]
Ancion, Arnaud [4 ]
Seidel, Laurence [5 ]
Lancellotti, Patrizio [4 ]
Cavalier, Etienne [3 ]
机构
[1] CHU Sart Tilman, Dept Clin Chem, Univ Hosp Liege, Liege, Belgium
[2] Univ Liege, Dept Phys Med & Sport Traumatol, Liege, Belgium
[3] Univ Hosp Liege, Dept Clin Chem, Liege, Belgium
[4] Univ Hosp Liege, Dept Cardiol, Liege, Belgium
[5] Univ Hosp Liege, Biostat Dept, Liege, Belgium
关键词
fibrosis cardiac biomarkers; galectin-3; long distance running; marathon; running; ST2; ultratour; CARDIAC BIOMARKERS; MYOCARDIAL FIBROSIS; RUNNERS; DIAGNOSIS; PROGNOSIS;
D O I
10.1515/cclm-2019-0555
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Previous studies have suggested that exercising may induce cardiac damage. Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (ST2) are very interesting biomarkers for heart failure and myocardial fibrosis. We aimed to compare the kinetics of emerging fibrosis cardiac biomarkers as Gal-3 and ST-2 in endurance runners, and recreational runners before and after a running event represented by a marathon and an ultratrail event. Methods: Blood samples were taken from 19 healthy non-elite marathon runners (42 km), 27 ultratour runners (67 km), and 14 recreational runners who represented the control group (10 km) just before the run (T0), just after (T1) and 3 h after (T2), in order to analyze Gal-3, ST2, hsTnT, NT-proBNP, CKMB and hsCRP. We compared the percentage of evolution and the slopes obtained from T0 to T1 (pT0T1) and from T1 to T2 (pT1T2), between the different groups of runners participating in three different races. Results: Plasma cardiac biomarker concentrations increased significantly from baseline to immediately post-exercise and most of the time decreased over the subsequent 3-h period. For pT0T1 and pT1T2, the markers Gal-3 and ST2 showed a significant difference between types of run (p < 0.05 and p < 0.0001, respectively). During the recovery time, Gal-3 returned to the baseline values but not ST2 which continued to increase. Conclusions: Gal-3 and ST2 are considered as a reflection of cardiac fibrosis and remodeling. The evolution of both was different, particularly after the recovery time. ST2 values exceeding cutoff values at any time.
引用
收藏
页码:314 / 321
页数:8
相关论文
共 50 条
  • [31] SuPAR, Galectin-3 and ST2 Are Associated With Chronic Kidney Disease Progression in Patients With Heart Failure With Reduced Ejection Fraction
    Gordon, Jonathan S.
    Roehm, Bethany
    Xu, Pin
    McAdams, Meredith
    Grodin, Justin L.
    Hedayati, Susan
    CIRCULATION, 2022, 146
  • [32] Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients
    Gruson, Damien
    Ferracin, Benjamin
    Ahn, Sylvie A.
    Rousseau, Michel F.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 189 : 185 - 187
  • [33] Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
    Tyminska, Agata
    Kaplon-Cieslicka, Agnieszka
    Ozieranski, Krzysztof
    Budnik, Monika
    Wancerz, Anna
    Sypien, Piotr
    Peller, Michal
    Balsam, Pawel
    Opolski, Grzegorz
    Filipiak, Krzysztof J.
    DISEASE MARKERS, 2019, 2019
  • [34] Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip)
    Doerr, Oliver
    Walther, Claudia
    Liebetrau, Christoph
    Keller, Till
    Sommer, Thomas
    Boeder, Niklas
    Bayer, Matthias
    Bauer, Pascal
    Moellmann, Helge
    Gaede, Luise
    Troidl, Christian
    Voss, Sandra
    Bauer, Timm
    Hamm, Christian W.
    Nef, Holger
    CLINICAL CARDIOLOGY, 2018, 41 (09) : 1164 - 1169
  • [35] NT-proBNP Is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients
    Basuroy, R.
    Srirajaskanthan, R.
    Ramage, J.
    Sherwood, R.
    NEUROENDOCRINOLOGY, 2016, 103 : 44 - 44
  • [36] SURVEY OF SIX POTENTIAL CARDIAC BIOMARKERS IN DOGS WITH HEART DISEASE: CHROMOGRANIN-A, ENDOGLIN, GALECTIN-3, NT-PROBNP, ST2, AND OSTEOPONTIN
    Oyama, M. A.
    Machen, M. C.
    Trafny, D. J.
    Singletary, G. E.
    Gupta, R. C.
    Sainger, R.
    Sabbah, H. N.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2012, 26 (03) : 725 - 725
  • [37] Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure
    Wang, Chao-Hung
    Yang, Ning-I
    Liu, Min-Hui
    Hsu, Kuang-Hung
    Kuo, Li-Tang
    CARDIOLOGY JOURNAL, 2016, 23 (05) : 563 - 572
  • [38] Comparison of Soluble ST2, Pentraxin-3, Galectin-3, and High-Sensitivity Troponin T of Cardiovascular Outcomes in Patients With Acute Decompensated Heart Failure
    Yamamoto, Masayoshi
    Seo, Yoshihiro
    Ishizua, Tomoko
    Nakagawa, Daishi
    Sato, Kimi
    Machino-Ohtsuka, Tomoko
    Nishi, Isao
    Hamada-Harimura, Yoshie
    Sai, Seika
    Sugano, Akinori
    Baba, Masako
    Higuchi, Haruhiko
    Aonuma, Kazutaka
    Ohte, Nobuyuki
    Ieda, Masaki
    JOURNAL OF CARDIAC FAILURE, 2021, 27 (11) : 1240 - 1250
  • [39] Serial soluble ST2 and galectin-3 measurement and its association with LV systolic and diastolic function in chronic heart failure patients after acute decompensation
    Protasov, V. Vladimir
    Skvortsov, A.
    Koshkina, D.
    Narusov, O.
    Masenko, V.
    Tereschenko, S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 102 - 102
  • [40] Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction
    Lax, Antonio
    Sanchez-Mas, Jesus
    Asensio-Lopez, Maria C.
    Fernandez-Del Palacio, Maria J.
    Caballero, Luis
    Garrido, Iris P.
    Pastor-Perez, Francisco J.
    Januzzi, James L.
    Pascual-Figal, Domingo A.
    JACC-HEART FAILURE, 2015, 3 (01) : 50 - 58